Clinical Trials Browser

Phase 2 × Recurrence × Bortezomib × Clear all

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02654990 2024-07-12

PANORAMA_3

Phase 2 Completed

248 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT01913730 2023-12-13

Maintenance Therapy With Subcutaneous Bortezomib

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT04173585 2023-03-27

TEAM

Phase 2 Completed

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00464178 2022-07-20

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

7 enrolled 5 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00773838 2021-04-01

MK-0683-095

Phase 2 Completed

143 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT00381940 2021-03-24

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Phase 2 Completed

26 enrolled 14 charts

Hodgkin Disease, Recurrence

NCT03617484 2020-06-22

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Phase 2 Withdrawn

Recurrence, Lymphoma, Mantle-Cell

NCT02290431 2019-11-18

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

31 enrolled 19 charts

Multiple Myeloma, Recurrence

NCT02535806 2019-08-13

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Phase 2 Terminated

2 enrolled 11 charts

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00038571 2018-10-31

Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

Phase 2 Completed

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT00201877 2018-03-12

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Phase 2 Completed

25 enrolled 9 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Mantle-Cell

NCT01083602 2017-12-21

MACS1271

Phase 2 Completed

55 enrolled 11 charts

Multiple Myeloma, Recurrence

NCT00547534 2015-08-06

BVR

Phase 2 Completed

31 enrolled 9 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT00706953 2015-04-06

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT00335348 2013-01-09

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT00509379 2011-01-28

LYM-2023

Phase 2 Completed

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT00136591 2010-10-26

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

Phase 2 Terminated

Lymphoma, Follicular, Recurrence

NCT00508209 2010-06-22

Bortezomib and High-dose Melphalan at Myeloma Relapse

Phase 2 Unknown

Multiple Myeloma, Recurrence

NCT00148018 2008-07-10

Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

Phase 2 Terminated

Hodgkin Disease, Lymphoma, Recurrence